CLARIFIDE is a 3,000-marker (3K) DNA panel that was developed through collaboration between USDA-ARS and Illumina. CLARIFIDE delivers Genomic Predicted Transmitting Ability (GPTA) values for 30 production, health and type traits, and nine composite indexes. These predictions provide insights into animals’ future genetic potential early in an animal’s life.

“CLARIFIDE provides a cost-effective way for commercial dairy producers to take advantage of the many benefits of genomic testing,” says Nigel Evans, vice president of Pfizer Animal Genetics. “Genomics has been available in the dairy industry for the past few years, but has only been practical for a small number of elite animals. CLARIFIDE now puts genomic testing into the hands of commercial dairymen.”

With CLARIFIDE, commercial dairy producers can optimize selection, mating and management of Holstein, Jersey and Brown Swiss females. Dairy producers can identify the females — along with their daughters — that will be the genetic future of their herds.

Pfizer Animal Genetics has implemented CLARIFIDE in partnership with several commercial dairies from across the United States to demonstrate the value of the new tool in real-world situations. In addition, Pfizer Animal Genetics worked with the USDA Animal Improvement Programs Laboratory (AIPL) to transform the results of genetic evaluations into knowledge via customer tools and expertise to enhance on-farm application and decision-making. All of this, coupled with the fact that CLARIFIDE provides exceptional reliability in predicting genetic potential when compared with traditional Predicted Transmitting Abilities (PTA), make it a powerful tool for dairy producers.